^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Published date:
11/16/2020
Excerpt:
Recommendations…Second-Line Therapy…pembrolizumab or nivolumab are reasonable options that may be considered for appropriate candidates…
DOI:
0.1200/JCO.20.02672 Journal of Clinical Oncology
Source:
Title:
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Excerpt:
Immunotherapies...Immunotherapy with nivolumab and pembrolizumab can be considered in patients who are intolerant to, or have progressed under, approved tyrosine kinase inhibitors, pending EMA approval [III, B].
DOI:
10.1093/annonc/mdy308
Source:
Excerpt:
Hepatocellular Cancer: Useful in certain circumstances...Nivolumabc,6 (if ineligible for tyrosine kinase inhibitors [TKIs] or other anti-angiogenic agents)...
Source:
Title:
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Published date:
01/01/2022
Excerpt:
...743 patients were randomly assigned to treatment (nivolumab, n=371; sorafenib, n=372). At the primary analysis, the median follow-up for overall survival was 15·2 months (IQR 5·7-28·0) for the nivolumab group and 13·4 months (5·7-25·9) in the sorafenib group. Median overall survival was 16·4 months (95% CI 13·9-18·4) with nivolumab and 14·7 months (11·9-17·2) with sorafenib (hazard ratio 0·85 [95% CI 0·72-1·02]; p=0·075; minimum follow-up 22·8 months)...
DOI:
https://doi.org/10.1016/S1470-2045(21)00604-5
Trial ID:
